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Transcriptome sequencing provides a far more precise and informative view of tumor biology 
than has hitherto been available. We sequenced the transcriptomes of 253 primary 
Medulloblastoma (MB) (~90M paired-end reads) with full clinical annotation, methylation 
and copy number profiles. 
 
We find that MB may be defined as four transcriptional subgroups but the increased 
sensitivity of RNA-seq shows Group3 and Group4 MB tumors to exist along a dichotomous 
continuum of expression whereby tumors may exist as a series of intermediates. Moreover, 
this continuum is clinically significant; the more “Group3–like” an individual the greater the 
frequency of high-risk clinico-pathological/biological features and risk of death. Deriving a 
score to denote an individuals position along the continuum significantly outperforms the 
traditional four-subgroup model as a predictor of survival and reveals a strong correlation 
with MYC and MYC target expression. 
 
By analysing the abundance of isoforms we were able to catalogue the predominant isoform 
expressed in MB and discover sub-group specific isoforms. De novo transcriptome assembly 
identifies several thousand previously undescribed transcripts/isoforms several hundred of 
which are sub-group specific with predicted coding potential. Fusion transcripts include 
predominantly PVT1 fusions and less frequently SUFU, MYCN. RNA single-nucleotide variants 
were also identified including subgroup specific RNA-editing events and allele specific 
expression. Several of these novel transcriptional events were selected for validation by qRT-
PCR/Sequencing. 
 
These findings raise important questions regarding the distinct nature of the Group3/Group4 
subgroups particularly as they relate to risk stratification as well as providing a first highly 
detailed landscape of the MB transcriptome. 
